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a  b  s  t  r  a  c  t
The  seven-valent  pneumococcal  conjugate  vaccine  (PCV7)  was  added  to the UK  national  immunisation
programme  in  September  2006.  PCV13  replaced  PCV7  in  April  2010.  As  carriage  precedes  disease  cases
this study  collected  carried  pneumococci  from  children  each  winter  from  2006/7  to  2010/11  over  PCV
introduction.  Conventional  microbiology  and  whole  genome  sequencing  were  utilised to characterise
pneumococcal  strains.
Overall  prevalence  of pneumococcal  carriage  remained  stable.  Vaccine  serotypes  (VT)  decreased
(p  <  0.0001)  with concomitant  increases  in non-vaccine  serotypes  (NVT).  In  winter  2010/11  only  one
isolate  of  PCV7  VT  was  observed  (6B). PCV13  unique  VTs  decreased  between  winters  immediately  pre-
ceding  and  following  PCV13  introduction  (p =  0.04). Signiﬁcant  decreases  for VTs 6B,  19F,  23F  (PCV7)
and  6A (PCV13)  and  increases  for  NVT  21,  23B,  33F  and  35F  were  detected.  The serotype  replacementhole genome was  accompanied  by  parallel  changes  in  genotype  prevalence  for  associated  sequence  types  with  clonal
expansion  contributing  to replacement.  By  winter  2010/11,  serotype  coverage  of  PCV7  and  PCV13  was
1%  and  11%  respectively.
VT  replacement  was  observed  for  PCV7  and  PCV13  serotypes.  Conjugate  vaccine  design  and  use  requires
continuous  monitoring  and  revision.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
14.5 million serious disease cases in children under ﬁve years
ld were caused annually by Streptococcus pneumoniae globally
n the pre-vaccine era [1]. In England and Wales approximately
800 invasive pneumococcal disease (IPD) cases in all age groups
ere estimated to occur every year before PCV7 introduction [2].
he pneumococcus is frequently carried asymptomatically in the
asopharynx. Carriage occurs in approximately 30% of children
nder ﬁve years old in the UK and is a precursor to disease [3]. This
s largely comparable with other high-income countries although
∗ Corresponding author at: Mailpoint 814, Level C, South Academic Block,
outhampton General Hospital, Southampton SO14 6YD, UK.
el.: +44 02381 208895.
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
carriage rates of up to 70% have been observed within Europe [4–6].
High carriage rates are reported for resource-poor countries, cor-
relating with higher disease rates [1].
The primary pneumococcal virulence factor is the polysac-
charide capsule, which is classiﬁed into serotypes based on
immunogenic properties. Serotypes vary in prevalence, geo-
graphical distribution and invasive potential [7,8]. Pneumococcal
conjugate vaccines (PCVs) target a limited number of the >90
recognised pneumococcal serotypes. The 7-valent pneumococcal
conjugate vaccine (PCV7, Prevenar7TM – Pﬁzer) includes seven
pneumococcal polysaccharides particularly associated with inva-
sive disease. PCV7 was added to the UK national immunisation
programme in 2006 [9]. The 13-valent PCV (PCV13, Prevenar13TM
– Pﬁzer) contains six additional serotypes and superseded PCV7 in
the UK in April 2010 [10].
Since PCV7 introduction, serotype replacement was  reported for
both carriage and disease in the UK, motivating the introduction of
PCV13 [2,3].
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The diversity of the pneumococcus allows rapid response to
elective pressure exerted by wide spread immunisation. It is there-
ore important to describe and monitor serotype and genotype of
oth carriage and disease to understand pneumococcal population
ynamics. Whole genomes offer a resource capable of screening
equence types (ST) and infer serotype as well as high-resolution
enome wide analysis and comparisons. We  sought to integrate
ext generation sequencing technologies into routine microbio-
ogical surveillance. Here we report a continuation of observations
ade for the ﬁrst three study winters during which only PCV7 had
een introduced, through two further winters surrounding PCV13
ntroduction.
. Methods
Nasopharyngeal swabs were collected from children aged 4
ears and under during ﬁve consecutive winters, October–March
006/7–2010/11. The initial three years of the study have been pre-
iously been described [3,11]. Brieﬂy, guardians were approached
ithin Southampton General Hospital outpatient department.
ritten informed consent was obtained with ethical approval from
outhampton and South West Hampshire Research Ethics Commit-
ee ‘B’ (REC 06/Q1704/105). The child swabbed was not necessarily
he child attending clinic but a sibling. One child per family was
wabbed. Age was the primary exclusion criteria. Rayon tipped
ranswabs (Medical wire, Corsham, UK) in charcoal Amies media
ere plated onto Columbia Colistin Naladixic Acid agar at Pub-
ic Health England (PHE) regional laboratory, Southampton within
 h. Presumptive S. pneumoniae were plated on Columbia blood
gar with an optochin disc and conﬁrmed with a ≥14 mm diam-
ter inhibition zone. Up to 10 well-isolated pneumococcal colonies
or each initial plate were stored at −70 ◦C. Sampling continued
ntil ≥100 S. pneumoniae were collected each winter. In winterl lines denote the time period between which the signiﬁcant change was  observed.
ints
2010/11 a questionnaire was  completed by the guardian to deter-
mine if the participant had likely received age appropriate doses
of PCVs.
Illumina sequencing was  performed at the Wellcome Trust
Sanger Institute with 75 bp paired-ends. Data is deposited in
the European nucleotide database with accession numbers:
ERR044859: ERR044953, ERR044955: ERR044987, ERR044989:
ERR048210, ERR048212: ERR045394, ERR045396: ERR045400,
ERR045402: ERR045413, ERR045415: ERR045431, ERR045433,
ERR045434, ERR045436: ERR047110, ERR047112: ERR047149,
ERR047151: ERR047163. De novo assembly was  performed using
Velvet assembler [12] and Velvet optimiser [13]. Serotype was
inferred from whole genome data using an in silico adaptation of
the Centres for Disease Control and Prevention PCR for deducing
serotype [14], the presence of known serotype speciﬁc sequences in
assemblies and mapping against known capsular loci as previously
described [15,16]. Phenotypic serotyping was  used if the genetic
basis for serotype was  unknown. MLST was  determined from whole
genomes as previously described [16].
To assess changes in prevalence, conﬁdence intervals (CI) were
calculated at 95% conﬁdence. Signiﬁcant changes in proportions
between two groups were detected using Fisher’s exact test with
two-tailed p-values.
3. Results
1712 swabs were collected between winters 2006/7 and
2010/11. 519 pneumococci were isolated from which 516 genomes
were available to deduce epidemiological data. The overall carriage
rate was  30% (CI, 28–32%). The carriage rate remained stable with
no signiﬁcant differences between 2006/7 and any other year, with
p-values of >0.1 (Fig. 1). The appropriate number of doses of PCV7
or PCV13 had been received for 91% (CI, 85–97%) of non-carriers
R.A. Gladstone et al. / Vaccine 33 (2015) 2015–2021 2017
observ
a
g
3
n
s
a
t
s
p
r
[
c
(
6
r
(
W
O
n
d
a
i
f
a
6
i
c
s
1
1
1Fig. 2. Temporal prevalence of PCV7 serotypes. *Signiﬁcant decrease 
nd 88.79% (CI, 85–97%) of carriers in winter 2010/11 according to
uardian responses.
.1. Deriving serotype from genotype
Serotyping from whole genome data allowed greater discrimi-
atory power than PCR methods and detection of newly described
erotypes for which other methods were not yet available, with the
dditional potential for discovery of novel variation deﬁning puta-
ive novel serotypes. We  documented sequence variation within
erotypes, by looking at a number of serotype-deﬁning genes for
revalent serotypes. Whilst within-serotype capsular polysaccha-
ide gene variation has been previously thought to be limited
15,17] we observed considerable genetic variation in capsular spe-
iﬁc genes within serogroup 6, serotypes 15B/C, 19A, 19F and 21
Supplementary Table 7).
Serogroup 6 was the most prevalent serogroup, 6A (n = 38),
B (n = 45) and 6C (n = 44). Genome derived serotype inference
esulted in the detection of single isolates of serotype 6D [18].
Notably one non-synonymous single nucleotide polymorphism
SNP) observed in this study resulted in a change from Ala150Thr in
ciN in a 6A background. This SNP was subsequently reported by
liver et al. to result in a hybrid serological proﬁle putatively desig-
ated NVT 6F [19]. In total there were three WciN  6A alleles. The
ominant 6B WciN  allele was identical to the dominant 6A WciN
llele. Two additional 6B protein alleles also existed, each observed
n one isolate. The single representative of the 6D WciN  allele dif-
ered from the dominant 6C protein sequence by only one amino
cid (AA). Four WciP alleles were observed within each serotype
A, 6B and 6C with three variable positions in 6A and 6C and ﬁve
n 6B.
WcrL contains the discriminatory SNP between 11A/D. PCR
ould not differentiate these serotypes. All WcrL alleles within this
tudy were identical except in one isolate. No isolates contained the
1D non-synonymous SNP and all could be therefore designated
1A [20,21].
15B isolates have been reported to contain 8 repeats and
5C isolates contain 7 or 9 TA repeats, which allowed theired between base-line winter 2006/7 and ﬁnal study winter 2010/11
differentiation [22]. However two  additional isolates were
observed in this study to have only 6 TA repeats that would also
result in a non-functional O-acetyltransferase and consequently the
phenotype of 15C.
Serotypes 19A and 19F structurally differ due to varying
sequence and function of the Wzy  repeat unit polymerase [15,23].
Three distinct Wzy  alleles were observed within the 31 19A iso-
lates. The two  most prevalent Wzy  alleles differing by two  AAs were
found in multiple ST backgrounds, both observed within ST199,
the dominant 19A clone in this study. Two  distinct Wzy  alleles
were observed for 19F isolates, both circulating in the population
with equal prevalence. While for serotype 21 two equally circu-
lating alleles of Wzx  were observed belonging to different clonal
complexes.
3.2. Serotype replacement
Thirty-nine serotypes were observed. The only PCV7 VT present
in all winters was 6B, with a single isolate detected in winter
2010/11. Three VTs unique to PCV13 (6A, 19A and 3) and 9 NVTs
were observed in all winters. PCV7 VTs signiﬁcantly decreased
between winters 2006/7 and 2010/11 (p < 0.0001) with a concomi-
tant increase in NVTs (Figs. 1 and 2; Supplementary Table 1). The
prevalence of PCV13 VTs signiﬁcantly decreased between winters
2006/7 and 2010/11 (p < 0.0001) with a concomitant NVT increase.
PCV13 unique serotypes signiﬁcantly decreased (Fig. 1, p = 0.04)
between winters 2009/10 and 2010/11 (Figs. 1 and 3; Supplemen-
tary Tables 2 and 3).
By winter 2010/11 the prevalence of PCV7 VT in carriage was
only 1%, falling from 53% in 2006/7. PCV13 VT prevalence in 2006/7
was 68% (CI, 59–77%) dropping to 26% (CI, 18–35%) before PCV13
introduction, due to shared PCV7 serotypes. By winter 2010/11 only
11% of carried pneumococci were PCV13 VT (CI, 5–17%).
Signiﬁcant decreases between winters 2006/7 and 2010/11
were observed for PCV7 serotypes 6B (p < 0.01), 19F (p < 0.01),
23F (p < 0.01) and PCV7 vaccine related type (VRT)/PCV13 VT 6A
(p < 0.05) (Figs. 2 and 3, Supplementary Table 4). A non-signiﬁcant
increase (p = 0.07) was  observed for PCV13 VT 19A between winter
2018 R.A. Gladstone et al. / Vaccine 33 (2015) 2015–2021
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006/7 and winter 2009/10 before PCV13 introduction. A decrease
n PCV7 serotype 14 between winters 2006/7 and 2010/11 did not
each signiﬁcance (p = 0.06), however numbers were low (2006/7
 = 5, 2010/11 n = 0). PCV13 VT 5 was not observed in the data set.
luctuations observed for PCV serotypes 1, 3, 4, 7F, 9V and 18C were
ot signiﬁcant (p > 0.40).
Twenty-seven PCV13 NVTs were observed. Of the NVTs, signiﬁ-
ant increases between winters 2006/7 and 2010/11 were observed
or serotypes 21 (p < 0.01), 23B (p < 0.02), 33F (p < 0.01) and 35F
p < 0.01).
Non-signiﬁcant increases were observed for serotype 15A
p = 0.06) and 6C (p = 0.08, Fig. 4). Serotypes 6C and 11A had sig-
iﬁcant ﬂuctuations within the study period not detectable when
omparing winters 2006/7 and 2010/11 (Supplementary Table 5).
he increase of 6C between winters 2006/7 and 2008/9 was pre-
iously reported as a consequence of clonal expansion [24,25]. A
igniﬁcant decrease (p = 0.01) was then observed for 6 C between
inters 2008/9 and 2009/10 (Fig. 4).
.3. Sequence types
127 STs were observed, derived from whole genomes. 61% of
he STs were seen in only one winter, as a single or pair of iso-
ates. Only 8 STs were observed in all winters. Signiﬁcant changes
etween 2006/7 and 2010/11 were observed for seven ST’s: 138,
62 and 176 (decreases) and 100, 432, 439 and 1635 (increases)
Supplementary Table 6). Fluctuations observed between winters
006/7 and 2010/11 for the remaining 119 sequence types were
ot signiﬁcant (p > 0.10). 15 STs were shared between the two
ears. Seventeen clonal complexes (CCs, share 6 of 7 alleles) were
bserved encompassing 54 different STs. Changes for STs remained
igniﬁcant when CCs were taken into account except ST439 as part
f CC42 (p > 0.10).observed between base-line winter 2006/7 and ﬁnal study winter 2010/11
3.4. Serotype and ST associations
For serotypes with signiﬁcant changes between winters 2006/7
and 2010/11 there were also changes observed in the dominant
ST (Fig. 5, Supplementary Table 6). A signiﬁcant decrease (p < 0.01)
could be only observed for ST65 the dominant ST for 6A between
winter 2007/8 and 2010/11 after an initial increase of 6A following
PCV7 introduction.
Sixteen combinations of ST and serotype and 17 combinations of
CC and serotype were shared between the primary winter 2006/7
and the ﬁnal winter 2010/11. These serotype lineages accounted
for 39% (STs) and 59% (CC) of the isolates in 2010/11.
Isolates that shared an ST with VTs but express a NVT due to
capsule switching were detected. ST 414 was observed express-
ing NVT 16F (n = 1) and VT serotype 1 (n = 1). ST193 was  observed
expressing NVT serotype 21 (n = 11) and VT 19A (n = 1). ST199 was
observed expressing NVTs 15B (n = 14) and 15C (n = 7) and VT 19A
(n = 23).
4. Discussion
Signiﬁcant changes in prevalence of PCV7 VTs and NVTs previ-
ously reported continued to be observed through winter 2009/10
to the ﬁnal winter (2010/11) [3]. This suggests that changes to
serotype distribution are stable, in line with PCV use. Serotypes
were known to ﬂuctuate temporally before PCV introduction as part
of natural cycles [26]. This phenomenon could explain within-study
ﬂuctuation of NVTs 11A and 6C. PCV7 could also have impacted
prevalence of vaccine related serotype 6A during the study period
through cross-reactive antibodies [27,28], post PCV7 6A increases
were observed in the Netherlands. This may  have contributed to
the observation that PCV13 VT decreased after PCV13 introduc-
tion [6]. Conversely there is evidence that cross-protection does not
occur for 19A [29]. Other observed changes in prevalence may  reach
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ncrease within study not observable between base-line winter 2006/7 and ﬁnal stu
igniﬁcance in winters following 2010/11, but the ability to detect
hanges could be limited by the sample size. Further surveillance is
eeded to observe whether changes are maintained. Understand-
ng of multiple serotype colonisation, particularly the detection
f minority serotypes may  further inform post PCV pneumococcal
arriage dynamics. Whilst additional samples were stored, prelim-
nary analysis of multiple colonies in the primary study winters
ig. 5. Temporal prevalence of STs associated with changes in serotype prevalence betwee
006/7 and ﬁnal study winter 2010/11. # Signiﬁcant change within study observable betwase between base-line winter 2006/7 and ﬁnal study winter 2010/11. # Signiﬁcant
inter 2010/11
2006/7–2008/9 did not allow detection of multiple serotype coloni-
sation. This traditional culture based approach is known to be less
sensitive to alternative methods, such as microarray, for detecting
multiple serotype colonisation [30].The association between serotype and ST is well established and
evident in this study. Clonal expansions of STs contributed to both
ﬂuctuations in serotype prevalence within the study such as 6C
n winter 2006/7 and winter 2010/11. *Signiﬁcant change between base-line winter
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T1692, and sustained changes in prevalence for example serotype
1 (ST432) and 23B (ST439) [25].
ST and serotype combinations detected that were indicative of
apsule switch had historically been documented in the pneumo-
occal MLST database in the pre-PCV era [31]. Additionally the
ajority of isolates (59%) in winter of 2010/11 were of serotype
nd ST combinations also present in winter of 2006/7 and are
herefore increased prevalence of established clones. Both ﬁnd-
ngs suggest that the majority of replacement involves lineages
lready present in the population, complimenting previous ﬁnd-
ngs that vaccine-escape isolates were a consequence of expansion
f existing lineages [32].
.1. Geographic speciﬁcity of carriage
Independent carriage studies from the UK and US also reported
o detectable change in the carriage rate [32–35]. Our carriage rate
etter reﬂected observations from the US being lower than reported
lsewhere in the UK but consistent with other Hampshire studies
36]. A substantial increase in 19A in both carriage and disease was
eported in the US where 19A was ranked ﬁrst in carriage for iso-
ates collected in 2008/09, whereas 19A increases before PCV13
ntroduction were not signiﬁcant in this study [34,37].
The rank order of prevalence of the top 10 PCV13 NVT in the
inter 2010/11 shared eight of the top 10 NVT reported for another
K study and interestingly also in the US study despite being geo-
raphically disparate [33,35]. Furthermore when looking at the
ank order of prevalence for the top 10 PCV13 NVT in post PCV car-
iage in children from a selection of countries (UK, US, Netherlands
nd Kenya), serotypes 11A, the 15B/C, 15A and US were reported
n all four countries [38,39]. This was despite differing use of PCVs
ith Kenya introducing the 10-valent PCV where PCV13 VT 19A
nd 6A were still highly prevalent. The exact order of prevalence
iffered in each location but these comparisons illustrate similar-
ties between distant populations that could help predict changes
n other locations but also demonstrate geography-speciﬁc preva-
ence for which on-going local surveillance is needed.
.2. From carriage to disease in the UK
A 98% reduction in PCV7 VT IPD in children less than two years
ld was reported between 2000–06 and 2009–10, mirroring the
ear complete removal of PCV7 VT carriage in this study [2].
NVT replacement also occurred in disease, with PHE reporting
 68% increase in NVT IPD in children less than 2 years of age [2].
n carriage, replacement was near complete and the overall car-
iage rate remained unchanged whilst for disease the reduction in
CV7 VT was not completely offset by increases in NVT disease. In
009–2010 a 34% reduction in the annual incidence of all IPD cases
rom that of 2000–2006 was reported, a smaller reduction than of
T IPD as a result of serotype replacement [2]. The key serotypes
nvolved in PCV7 disease replacement in 2010 were reported to be
F, 19A and 22F [2]. Changes in these serotypes in carriage were not
igniﬁcant, which may  be a factor of sample size. Serotypes 7F and
9A have a high invasive disease potential (odds ratios for invasive
isease of 4.7 and 1.1 respectively) [8,40], whilst an odds ratio for
2F of zero was  previously calculated, but isolate numbers were
ow [40].
Prevention of invasive disease cases through preventing car-
iage (herd protection) in addition to direct prevention of invasion
s a key feature of PCVs that contributes to their cost effectiveness.
he signiﬁcant reduction in PCV13 unique serotypes in carriage
bserved in this study should increase the impact of PCV13 beyond
ts direct immunogenic effects, indirectly via herd protection. A 50%
eduction in PCV13 speciﬁc IPD in children under two years of age
as reported by PHE in the year following PCV13 introduction [41]. 33 (2015) 2015–2021
Whole genome data has proved a valuable resource for the
derivation of routine pneumococcal typing to inform epidemio-
logical analysis with the opportunity for further in-depth analysis.
Additionally the availability of large collections of pneumococcal
sequence data results in the opportunity to detect variation such
as genetic variation affecting protein sequence within a serotype.
A single point mutation within a capsular gene encoding, for
example a glycosyltransferase, can result in different substrate
speciﬁcity that in turn alters capsular biosynthesis. SNPs with
such consequences are well documented including the 6F variant
demonstrated to be immunologically distinct to 6A [19]. Therefore
further novel variation also have the potential to affect capsule
expression, immunological properties and ultimately current or
future vaccine efﬁcacy and effectiveness [19,42].
The data though further highlights that our understanding
of serotype, particularly the genotypic contribution, is not yet
complete. Documented variation could give direction to contin-
ued discrimination of serotypes and increase speciﬁcity of future
genotypic inference, so that surveillance, serotype speciﬁc vaccine
efﬁcacy, modelling of future replacement, and cost effectiveness
estimates are as accurate as possible.
This study shows signiﬁcant changes in prevalence for individ-
ual PCV7 serotypes detected by the ﬁfth study winter. This study
similarly shows a signiﬁcant decrease in PCV13 VT between winters
preceding and following PCV13 introduction although this cannot
be directly attributed to PCV13 as multiple factors could have con-
tributed to this, including PCV7 serogroup cross-reactivity, natural
ﬂuctuations and movement back towards equilibrium [26,27,37].
Guardian reporting for winter 2010/11 suggests age appropriate
PCV immunisation was  high for our study population, further infor-
mation of the vaccine status of the individuals would help tease
apart the indirect and direct effects for PCV13. On-going substantial
serotype replacement further indicates that continuing surveil-
lance of carriage in addition to IPD is required to inform the future
of pneumococcal vaccination.
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